Related Experiment Videos
Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in
1Tulane University Health Sciences Center, New Orleans, LA, USA.
Insights
Cardiovascular disease is a major risk for dialysis patients. Managing calcium and phosphorus levels, aided by imaging like electron beam computed tomography (EBCT), can help reduce calcific complications and cardiac events.
Area of Science:
- Nephrology
- Cardiology
- Radiology
Background:
- Cardiovascular disease (CVD) is the primary cause of mortality in end-stage renal disease (ESRD) patients, responsible for nearly half of all deaths.
- Elevated serum phosphorus and calcium-phosphorus (Ca x P) product are linked to CVD in chronic renal failure, with mismanagement of mineral metabolism contributing to soft tissue calcification.
- ESRD patients often experience hyperphosphatemia and excess calcium, increasing the Ca x P product and leading to calcific complications.
Purpose of the Study:
- To investigate the role of electron beam computed tomography (EBCT) in assessing cardiovascular calcification in hemodialysis patients.
- To explore the association between Ca x P product, calcium intake, and calcific complications in ESRD patients.
- To evaluate the utility of EBCT in monitoring disease progression and guiding therapeutic strategies.
Main Methods:
- Utilized electron beam computed tomography (EBCT) to detect and quantify calcification in various tissues, including coronary arteries, cardiac structures, and valves.
- Correlated EBCT findings (calcium scores) with serum phosphorus levels and Ca x P product in hemodialysis patients.
- Analyzed daily calcium intake from calcium-based phosphate binders in patients with and without calcification.
Main Results:
- Hemodialysis patients exhibited high calcium scores on EBCT, significantly associated with elevated Ca x P product.
- Patients with detected calcification had consumed twice the daily calcium from calcium-based phosphate binders compared to those without calcification.
- EBCT proved sensitive in detecting and quantifying calcific changes.
Conclusions:
- Managing calcium and phosphorus metabolism is crucial for reducing cardiovascular risk in dialysis patients.
- Strategies such as low-calcium dialysate, less calcemic vitamin D analogs, and calcium-free phosphate binders are recommended.
- EBCT serves as a valuable tool for initial assessment and ongoing monitoring of cardiovascular calcification in ESRD patients, aiding therapeutic adjustments.
Abstract:
Cardiovascular disease is the leading cause of death in dialysis patients, accounting for nearly half of all deaths among end-stage renal disease (ESRD) patients. Even young dialysis patients are at risk. Cardiovascular disease in chronic renal failure patients has been associated with elevated serum phosphorus levels and elevated calcium-phosphorus (Ca x P) product, and mismanagement of calcium and phosphorus metabolism has been implicated as a major factor in the development of soft tissue calcification and cardiovascular disease. ESRD patients frequently face hyperphosphatemia as well as excess calcium load, which elevate the Ca x P product, thereby contributing to the development of calcific complications. Electron beam computed tomography (EBCT) can be used to detect different calcification stages in a variety of tissues, and is a sensitive tool for detecting calcified coronary artery plaques as well as cardiac and valvular calcifications. Hemodialysis patients have high calcium scores on EBCT imaging, and these are associated with elevations in Ca x P product. In a recent study, patients with calcification were found to have had twice the daily calcium intake from calcium-based phosphate binders than patients without calcification. Strategies to reduce cardiac risk in hemodialysis patients include use of a dialysate low in calcium, use of vitamin D analogs that are less calcemic, and use of calcium-free phosphate binders. EBCT can be a useful adjunct to these therapies, since it permits sensitive and quantitative initial assessment, as well as ongoing monitoring of disease progression.